The FDA has approved Cologuard Plus (Exact Sciences), a new at-home multitarget stool DNA test, for colorectal cancer (CRC) screening in average-risk adults ≥45 years old. Cologuard, the first FDA-approved multitarget stool DNA test, has been available since 2014.1
COLORECTAL CANCER SCREENING — Guidelines recommend screening average-risk adults for CRC beginning at age 45. Colonoscopy is generally the preferred method of screening; it can detect precancerous adenomas and allows for biopsy and removal of lesions during the procedure. Fecal immunochemical...
- Drugs for Open-Angle Glaucoma
- A Fixed-Dose Combination of Meloxicam and Rizatriptan (Symbravo) for Migraine
- In Brief: Epinephrine 1 mg Nasal Spray (neffy)
- In Brief: A New Indication for Tenecteplase (TNKase)
- Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia (online only)
- Revakinagene Taroretcel (Encelto) – A Gene Therapy for Idiopathic Macular Telangiectasia (online only)
RELEASE
Miudella (Sebela), a copper intrauterine device (IUD), has been approved by the FDA for prevention of pregnancy for up to 3 years. Miudella is the second copper IUD to be approved in the US; ParaGard, which contains more copper and is approved for up to 10 years of use, was approved in 1984. Four hormonal IUDs (Mirena, Liletta, Skyla, Kyleena) that release the progestin levonorgestrel are also available for pregnancy prevention (see Table 2).1
IUDs — IUDs are highly effective in preventing pregnancy. Once inserted, they provide long-term contraception and require no adherence other than an office visit for replacement. Fertility returns rapidly upon removal. IUDs are considered safe for use in most women, including adolescents and nulliparous women. They do not protect against sexually transmitted infection (STIs).2,3
THE NEW …